Physician profile
May J Chow
NPI 1518918879
$24,002.69
in general payments reported to CMS, 2019-2025
37 companies · $2,028 in 2025
The $2,028 reported for 2025 was more than what 76% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,746 · 2020: $1,844 · 2021: $3,006 · 2022: $3,902 · 2023: $3,494 · 2024: $3,984 · 2025: $2,028.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,505.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,505.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $2,857.71 | 2019-2025 | |
| Galderma Laboratories, L.P. | $1,805.37 | 2019-2025 | Aklief, Dysport |
| Ucb, INC. | $1,605.92 | 2019-2025 | Bimzelx, Cimzia |
| Celgene Corporation | $1,555.00 | 2019 | |
| Dermavant Sciences, INC. | $1,482.99 | 2022-2024 | Vtama |
| Abbvie INC. | $1,477.81 | 2019-2025 | Rinvoq, Skyrizi |
| Pfizer INC. | $1,446.69 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $1,241.34 | 2021-2025 | Sotyktu |
| Genzyme Corporation | $1,136.54 | 2019-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $1,057.65 | 2019-2024 | Cabtreo, Arazlo, Jublia |
| Leo Pharma INC. | $963.52 | 2019-2024 | Adbry |
| Sun Pharmaceutical Industries INC. | $857.42 | 2019-2025 | Winlevi, Absorica Ld |
| Arcutis Biotherapeutics, INC. | $833.24 | 2023-2025 | Zoryve |
| Almirall LLC | $747.39 | 2019-2025 | Klisyri, Seysara |
| Incyte Corporation | $690.67 | 2021-2024 | Opzelura |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $660.19 | 2019-2025 | Dupixent |
| Epi Health, LLC | $592.14 | 2019-2022 | |
| Amgen INC. | $590.98 | 2019-2025 | Otezla, Otezla |
| Lilly USA, LLC | $561.63 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Janssen Biotech, INC. | $347.50 | 2019-2025 | Tremfya, Simponi, Simponi Aria |
| Dermira, INC. | $329.00 | 2019-2021 | |
| Organon LLC | $208.75 | 2025 | Vtama |
| Sandoz INC. | $168.75 | 2020-2021 | |
| Mayne Pharma Commercial LLC | $164.16 | 2019-2025 | |
| Encore Dermatology INC. | $160.60 | 2019-2020 | |
| Allergan, INC. | $128.53 | 2019 | |
| Biofrontera INC. | $88.11 | 2023 | Ameluz, Xepi, Bf-Rhodoled |
| Boehringer Ingelheim Pharmaceuticals, INC. | $43.58 | 2023-2024 | Cyltezo |
| Medimetriks Pharmaceuticals, INC. | $31.81 | 2022 | |
| Helsinn Therapeutics (U.S.), INC. | $29.46 | 2019-2023 | Valchlor |
| Sanofi-Aventis U.S. LLC | $28.42 | 2021 | |
| Glenmark Therapeutics INC. | $26.00 | 2019 | |
| Vyne Pharmaceuticals INC. | $21.95 | 2021 | |
| Fresenius Kabi USA, LLC | $19.54 | 2023 | |
| Bausch Health US, LLC | $17.03 | 2019 | |
| Journey Medical Corporation | $14.03 | 2024 | |
| Sebela Pharmaceuticals INC. | $11.27 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw May Chow listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.